spacer
home > ebr > spring 2002 > the patenting of biotechnology in canada
PUBLICATIONS
European Biopharmaceutical Review

The Patenting of Biotechnology in Canada

Unlike in the US or Europe, there are no clear guidelines in Canada governing patenting requirements in the field of biotechnology, and case law is limited. In the absence of domestic policy or law, the Canadian Patent Office is greatly influenced by the practices of the US and European patent offices. This approach has been endorsed by the Canadian courts, who have frequently turned to other jurisdictions for guidance when domestic law is lacking. In recent decisions, such as the Federal Court Trial Division in Monsanto Canada Inc. versus Schmeiser (2001), 12 C.P.R. (4th) 204 (F.C.T.D.); the Federal Court of Appeal in The President and Fellows of Harvard College versus Canada (Commissioner of Patents) (2000), 7 C.P.R. (4th) 1 [hereinafter Harvard College, Supra]; and the Supreme Court of Canada in Free World Trust versus Electro Sante Inc. (2000), 9 C.P.R. (4th) 168, the Courts espoused the value of referring to US case law and practice to provide guidance in the development of Canadian patent law.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Anita Nador, Partner in the Biotechnology and Pharmaceutical Practice Group at Bereskin & Parr

Anita Nador is a Partner with Bereskin & Parr in their Biotechnology and Pharmaceutical Practice Group. She received a BA in Molecular Biophysics and Biochemistry from Yale University in 1986 and undertook research at Harvard Medical School and at a major Canadian pharmaceutical company before obtaining a Law degree from the University of Toronto in 1993.
Anita was called to the bar of Ontario in 1995 and is a registered Canadian patent and trademark agent. She is also registered to practice before the US Patent Office. Anita's practice is specialised in the area of intellectual property - particularly in biotechnology and pharmaceutical patent - plant breeders' rights, and trademark and licensing matters.

spacer
Anita Nador
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers
 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement